NEW:

Evidence

Click below to explore the latest additions to VERI


PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 2 days nivolumab Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 2 days
AGK-BRAF fusion AGK-BRAF fusion	Melanoma Melanoma	FORE-8394 Resistant: C4 – Case Studies ASCO 2023 - 3 days FORE-8394 Resistant: C4 – Case Studies ASCO 2023 - 3 days
ERBB3 expression ERBB3 expression	Breast Cancer Breast Cancer	U3-1402 Sensitive: C3 – Early Trials ASCO 2023 - 3 days U3-1402 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
BRAF V600 BRAF V600	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
MGMT unmethylation MGMT unmethylation	Glioblastoma GBM	UCPVax Sensitive: C3 – Early Trials ASCO 2023 - 3 days UCPVax Sensitive: C3 – Early Trials ASCO 2023 - 3 days
BRAF V600 BRAF V600	Glioma Glioma	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	BL-B01D1 Sensitive: C3 – Early Trials ASCO 2023 - 3 days BL-B01D1 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
HER-2 expression HER-2 expression	Lung Cancer Lung Cancer	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
BRAF V600 BRAF V600	Ovarian Cancer Ovarian Cancer	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
BRAF V600 BRAF V600	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	docetaxel Resistant: C3 – Early Trials Lung Cancer - 3 days docetaxel Resistant: C3 – Early Trials Lung Cancer - 3 days
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: C3 – Early Trials Future Medicine - 3 days alectinib Sensitive: C3 – Early Trials Future Medicine - 3 days
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + BCA101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days pembrolizumab + BCA101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
FOLR1 expression FOLR1 expression	Ovarian Cancer Ovarian Cancer	STRO-002 Sensitive: C3 – Early Trials ASCO 2023 - 3 days STRO-002 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	dalpiciclib Sensitive: C3 – Early Trials ASCO 2023 - 3 days dalpiciclib Sensitive: C3 – Early Trials ASCO 2023 - 3 days
RSPO3 fusion RSPO3 fusion	Gastrointestinal Stromal Tumor GIST	pembrolizumab + CGX1321 Sensitive: C3 – Early Trials ASCO 2023 - 3 days pembrolizumab + CGX1321 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO 2023 - 3 days trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO 2023 - 3 days
IDH1 mutation IDH1 mutation	Glioma Glioma	PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
IDH2 mutation IDH2 mutation	Glioma Glioma	PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
HER-2 expression HER-2 expression	Breast Cancer Breast Cancer	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
PTEN overexpression PTEN overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: C3 – Early Trials ASCO 2023 - 3 days afatinib Sensitive: C3 – Early Trials ASCO 2023 - 3 days
BRAF V600 BRAF V600	Colorectal Cancer CRC	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days
HER-2 positive HER-2 positive	Colorectal Cancer CRC	fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials ASCO 2023 - 3 days fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials ASCO 2023 - 3 days
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	dostarlimab-gxly Sensitive: B - Late Trials ASCO 2023 - 3 days dostarlimab-gxly Sensitive: B - Late Trials ASCO 2023 - 3 days
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: B - Late Trials ASCO 2023 - 3 days pembrolizumab Sensitive: B - Late Trials ASCO 2023 - 3 days
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	AZD3759 Sensitive: B - Late Trials ASCO 2023 - 3 days AZD3759 Sensitive: B - Late Trials ASCO 2023 - 3 days
HRD HRD	Prostate Cancer Prostate Cancer	talazoparib Sensitive: B - Late Trials ASCO 2023 - 3 days talazoparib Sensitive: B - Late Trials ASCO 2023 - 3 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: B - Late Trials ASCO 2023 - 3 days sacituzumab govitecan-hziy Sensitive: B - Late Trials ASCO 2023 - 3 days
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials ASCO 2023 - 3 days palbociclib Sensitive: B - Late Trials ASCO 2023 - 3 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Sensitive: B - Late Trials ASCO 2023 - 3 days abemaciclib Sensitive: B - Late Trials ASCO 2023 - 3 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	toripalimab Sensitive: B - Late Trials ASCO 2023 - 3 days toripalimab Sensitive: B - Late Trials ASCO 2023 - 3 days
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days
FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days
EGFR negative EGFR negative	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: C3 – Early Trials Cancer Med - 4 days bevacizumab Sensitive: C3 – Early Trials Cancer Med - 4 days
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C4 – Case Studies Gan To Kagaku Ryoho - 5 days osimertinib Resistant: C4 – Case Studies Gan To Kagaku Ryoho - 5 days
BRAF mutation BRAF mutation	Melanoma Melanoma	DAY101 Sensitive: C3 – Early Trials Cancer Chemother Pharmacol - 5 days DAY101 Sensitive: C3 – Early Trials Cancer Chemother Pharmacol - 5 days
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials Sci Rep - 5 days EGFR inhibitor Sensitive: C3 – Early Trials Sci Rep - 5 days
RET rearrangement RET rearrangement	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: C3 – Early Trials Cancer Res Treat - 6 days pralsetinib Sensitive: C3 – Early Trials Cancer Res Treat - 6 days
LDH elevation LDH elevation	Renal Cell Carcinoma RCC	axitinib Resistant: C3 – Early Trials Kidney Cancer - 6 days axitinib Resistant: C3 – Early Trials Kidney Cancer - 6 days